Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.

Journal: Journal of arrhythmia
Published Date: Dec 26, 2018

Abstract

BACKGROUND: Direct oral anticoagulants are the first-line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real-world, large-scale, clinical study on edoxaban has not been performed. Our ongoing postmarketing surveillance, ETNA-AF-Japan (doxaban reatment in routie clinical prctice in patients with non-valvular trial ibrillation; UMIN000017011), was designed to collect such data.

Authors

  • Takeshi Yamashita
    The Cardiovascular Institute Tokyo Japan.
  • Yukihiro Koretsune
    National Hospital Organization Osaka National Hospital Osaka Japan.
  • Mayumi Ishikawa
    Post Marketing Study Department Daiichi Sankyo Co. Ltd. Tokyo Japan.
  • Kazuhito Shiosakai
    Biostatistics & Data Management Department Daiichi Sankyo Co. Ltd. Tokyo Japan.
  • Seiji Kogure
    Post Marketing Study Department Daiichi Sankyo Co. Ltd. Tokyo Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals